| Tuesday, October 21, 2008 | ||
| 13:10:00 | Opening ceremony | |
| 13:15:00 | Michel Clavel lecture No risk, no fun | J. Verweij, P. Schöffski |
| 14:00:00 | Keynote lecture IGF-1 as an emerging target | J. Doroshow, Douglas none Yee |
| 15:15:00 | Plenary session 1 PI 3-kinase: which isoform to target? | B. Vanhaesebroeck |
| 15:15:00 | Plenary session 1 Molecular targets-state of the science A | A. J. Murgo |
| 15:15:00 | Plenary session 1 Notch as a potential therapeutic target in cancer | L. Miele |
| 15:15:00 | Plenary session 1 Met inhibition as a target in clinical oncology rationale and current achievements | F.A L.M. Eskens |
| 15:15:00 | Plenary session 1 Ret | S. A. Wells |
| Wednesday, October 22, 2008 | ||
| 08:00:00 | Workshop 1 Animal models in drug development | G. Adolf, J. L. Abbruzzese |
| 08:00:00 | Workshop 1 Opportunities for effectively using genetically engineered mice for drug discovery | C. Abate-Shen |
| 08:00:00 | Workshop 1 Imaging signalling pathways in animal models | A. Rehemtulla |
| 08:00:00 | Workshop 3 Pharmacogenomics in colon cancer | H. Lenz |
| 08:00:00 | Workshop 3 SNPs and pharmacogenetics | |
| 08:00:00 | Workshop 1 Pitfalls for drug discovery with “genetic” animal models | E. A. Sausville |
| 08:00:00 | Workshop 2 Paediatric Oncology | GILLES VASSAL, M. Smith |
| 08:00:00 | Workshop 2 Update on the application of the EU regulation | A. Saint-Raymond |
| 08:00:00 | Workshop 2 Early drug development in the clinics in the United States of America | P. C. Adamson |
| 08:00:00 | Workshop 3 Pharmacogenomics-where are we now? | W. D. Figg |
| 08:00:00 | Workshop 1 How naturally occurring cancers in dogs can inform the drug development path | C. Khanna |
| 08:00:00 | Workshop 2 Preclinical evaluation as a tool to prioritize compounds for paediatric development- NCI Programme | P. Houghton |
| 08:00:00 | Workshop 2 Preclinical evaluation as a tool to prioritize compounds for paediatric development-the EU Kidscancerkinome project | H. Caron |
| 08:00:00 | Workshop 2 Early drug development in the clinics in Europe | GILLES VASSAL |
| 08:00:00 | Workshop 3 Pharmacogenomics | A. Sparreboom |
| 08:00:00 | Workshop 3 Bioinformatics | |
| 10:15:00 | Workshop 6 Patient enrichment strategy in phase II | J. De Bono |
| 10:15:00 | Workshop 5 Inhibitors of 17alpha-hydroxylase/17,20-lyase | A. Reid |
| 10:15:00 | Workshop 6 Design and conduct of phase II trials for targeted agents | J. A. Zwiebel |
| 10:15:00 | Workshop 4 Experience with Phase 0 studies in non-oncology indications | |
| 10:15:00 | Workshop 4 Implementation of phase 0 trials | J.H. M. Schellens |
| 10:15:00 | Workshop 4 Use of phase 0-changes in cancer drug development | J. M. Collins |
| 10:15:00 | Workshop 4 Industry perspective | |
| 10:15:00 | Workshop 5 CYP-activated prodrugs as chemotherapeutics | Russell H. Plumb |
| 10:15:00 | Workshop 5 Targeting the CYP pathway | A. M. Burger, G. Demetri |
| 10:15:00 | Workshop 5 Novel Atypical retinoic acid metabolism blocking agents (RAMBAs)/CYP26 Inhibitors for breast cancer therapy | V. C. Njar |
| 10:15:00 | Workshop 6 Adaptive phase II trials | D. Berry |
| 10:15:00 | Workshop 4 Phase 0 trials-are they necessary? | E. Leo, J. Doroshow |
| 10:15:00 | Workshop 5 The evolution of CYPs from metabolising enzymes to potential targets in cancer development | L. Patterson |
| 10:15:00 | Workshop 6 Parallel phase II trials- European perspective | D. Lacombe |
| 10:15:00 | Workshop 6 Using biomarkers in phase II | J. Tabernero |
| 12:00:00 | Poster sessions | |
| 15:00:00 | Plenary session 2 Proffered papers | J. C. Soria, L. J. Helman |
| 16:30:00 | Plenary session 3 Molecular targets-state of the science B | A. Awada, P. Ivy |
| 16:30:00 | Plenary session 3 Drugging the cancer chaperone HSP90: From chemical biology with natural products to active drugs in the clinic | P. Workman |
| 16:30:00 | Plenary session 3 Proteasome | Kenneth C. Anderson |
| 16:30:00 | Plenary session 3 Death signalling | E. P. White |
| 16:30:00 | Plenary session 3 Protacs | K. Sakamoto |
| Thursday, October 23, 2008 | ||
| 08:00:00 | Plenary session 4 mTOR and autophagy | Bo Lu |
| 08:00:00 | Plenary session 4 Oncogenes and tumor suppressor genes control autophagy | G. Kroemer |
| 08:00:00 | Plenary session 4 Roel of autophagy in cancer resistance | |
| 08:00:00 | Plenary session 4 Targeting autophagic pathways | N. Zaffaroni, R. S. DiPaola |
| 08:00:00 | Plenary session 4 Novel therapeutic targets within the autophagic pathway | William N Hait |
| 10:15:00 | Plenary session 5 Her family | B. Burtness |
| 10:15:00 | Plenary session 5 Molecular targets-state of the science C | M.J.A. de Jonge, David M Spriggs |
| 10:15:00 | Plenary session 5 Polo-like kinases | P. Schöffski |
| 10:15:00 | Plenary session 5 Aurora kinases | B. Laffranchi |
| 10:15:00 | Plenary session 5 PARP | H. Calvert |
| 12:00:00 | Poster sessions | |
| 15:00:00 | Plenary session 6 Profferd papers | T. Lawrence, P. S. Steeg |
| 16:30:00 | Plenary session 7 Exploring translation initiation as a therapeutic target | J. Pelletier |
| 16:30:00 | Plenary session 7 Targeting the protein translation factor eIF4E for cancer therapy | J. Graff |
| 16:30:00 | Plenary session 7 Small molecule inhibitors of the human MDM2-p53 interaction as anticancer agents | S. Wang |
| 16:30:00 | Plenary session 7 Targeting protein translation and protein-protein interaction in cancer | Y. Pommier, H. Newell |
| 16:30:00 | Plenary session 7 Approaches for targeting protein-protein interaction | Stephen Fesik |
| Friday, October 24, 2008 | ||
| 08:00:00 | Plenary session 8 Role of siRNA in drug development | N. Caplan |
| 08:00:00 | Plenary session 8 RNA based technologies for target identification, validation and treatment | P. Ho, E. H. Rubin |
| 08:00:00 | Plenary session 8 microRNA and therapeutic applications | D. Cohen |
| 08:00:00 | Plenary session 8 Discovery of practical delivery systems for RNAi | |
| 08:00:00 | Plenary session 8 High-throughput RNAi screening using cell microarray technology | O. Kallioniemi |
| 10:15:00 | Plenary session 9 Imaging molecular targets | J. L. Tatum, Philip Kollmannsberger |
| 10:15:00 | Plenary session 9 Hypoxia imaging | K. A. Krohn |
| 10:15:00 | Plenary session 9 Apoptosis imaging | H. W. Strauss |
| 10:15:00 | Plenary session 9 Update on imaging tumor proliferation with PET | A. F. Shields |
| 10:15:00 | Plenary session 9 Applications of nanotechnology and molecular probes in cancer imaging | T. Meade |
| 12:00:00 | Poster sessions | |
| 14:00:00 | Plenary session 10 Challenges in the development of anti bodies and antibody conjugates | Chris H. Takimoto, J. M. Ford |
| 14:00:00 | Plenary session 10 Genentech: antibodies/antibody conjugates in development | S. Lutzker |
| 14:00:00 | Plenary session 10 Amgen: antibodies/antibody conjugates in development | D. Chang |
| 14:00:00 | Plenary session 10 Antibodies/antibody conjugates in development | |
| 14:00:00 | Plenary session 10 ImClone sytems: antibodies/antibody conjugates in development | E. Rowinsky |
| 15:45:00 | Closing ceremony | |
How We Rank